King's College London

Research portal

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future

Research output: Contribution to journalReview articlepeer-review

Yu Yan Tan, Peter Jenner, Sheng Di Chen

Original languageEnglish
Pages (from-to)477-493
Number of pages17
JournalJournal of Parkinson's Disease
Issue number2

Bibliographical note

Funding Information: This work was supported by the National Natural Science Foundation of China, Grant/Award Number: 81430022, 81771374, 81971187, 81971183; Shanghai Municipal Science and Technology Major Project, Grant/Award Number: 2018SHZDZX05; Innovation Program of Shanghai Municipal Education Commission, Grant/Award Number: 2017-01-07-00-01-E00046; Foundation of Shanghai Municipal Education Commission, Grant/Award Number: 2017NKX001. Publisher Copyright: © 2022 - The authors. Published by IOS Press.

King's Authors


Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce 'OFF' time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454